These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26607604)

  • 21. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
    Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
    Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
    Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
    Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
    Galliverti G; Tichet M; Domingos-Pereira S; Hauert S; Nardelli-Haefliger D; Swartz MA; Hanahan D; Wullschleger S
    Cancer Immunol Res; 2018 Nov; 6(11):1301-1313. PubMed ID: 30131378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HSP70 modified response against HPV based tumor.
    Farzanehpour M; Soleimanjahi H; Hassan ZM; Amanzadeh A; Ghaemi A; Fazeli M
    Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):228-34. PubMed ID: 23377813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.
    Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y
    Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
    Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
    Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.
    Mohit E; Bolhassani A; Zahedifard F; Seyed N; Eslamifar A; Taghikhani M; Samimi-Rad K; Rafati S
    Mol Immunol; 2013 Jan; 53(1-2):149-60. PubMed ID: 22926003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein.
    Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A
    Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
    Indrová M; Bieblová J; Rossowska J; Kuropka P; Pajtasz-Piasecka E; Bubeník J; Reinis M
    Int J Oncol; 2009 Jan; 34(1):173-9. PubMed ID: 19082488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
    N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
    Toubaji A; Hill S; Terabe M; Qian J; Floyd T; Simpson RM; Berzofsky JA; Khleif SN
    Vaccine; 2007 Aug; 25(31):5882-91. PubMed ID: 17602804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
    Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
    Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
    Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR
    Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.